Rob Abbott

Patients

Web editor Nicole Raleigh speaks with Rob Abbott, CEO and executive director of ISPOR, about the ins and outs and trends of HEOR.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.